AMRN
Amarin Corporation plc
NASDAQ · Healthcare · Biotechnology · IE
$13.63
−0.58%Aug 31, 2026, 12:15 UTC
Amarin presented new REDUCE-IT and mechanistic data at the European Society of Cardiology Congress 2026, expanding understanding of treatment adherence, long-term outcomes, and mechanisms of eicosapentaenoic acid.
Source:Jul 29, 2026, 11:00 UTC
Amarin Corporation plc reported its financial results for the second quarter ended June 30, 2026, highlighting global volume growth, lower operating expenses, and positive cash flow.
Jul 1, 2026, 12:30 UTC
The U.S. Supreme Court unanimously ruled in favor of generic drug manufacturers in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing the Federal Circuit and setting a new standard for induced patent infringement claims.
Source:Jun 4, 2026, 18:04 UTC
The Supreme Court ruled in favor of Hikma Pharmaceuticals in a patent infringement case against Amarin over skinny labeling.
Source: